Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 669

1.

Facts and reflections on COVID-19 and anti-hypertensives drugs.

Marin GH.

Drug Discov Ther. 2020 Mar 26. doi: 10.5582/ddt.2020.01017. [Epub ahead of print]

PMID:
32213760
2.
3.

Discovering drugs to treat coronavirus disease 2019 (COVID-19).

Dong L, Hu S, Gao J.

Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.

4.

Development of an algorithm using ultrasonography-assisted peripheral intravenous catheter placement for reducing catheter failure.

Kanno C, Murayama R, Abe-Doi M, Takahashi T, Shintani Y, Nogami J, Komiyama C, Sanada H.

Drug Discov Ther. 2020;14(1):27-34. doi: 10.5582/ddt.2019.01094.

6.

Efficacy of Chinese prescription Kangen-karyu for patient with metabolic syndrome.

Kitazawa T, Park CH, Hiratani K, Choi JS, Yokozawa T.

Drug Discov Ther. 2020 Mar 8;14(1):54-57. doi: 10.5582/ddt.2020.01003. Epub 2020 Feb 28.

7.

Association of moderately abnormal behavior and administered neuraminidase inhibitors.

Sugawara T, Ohkusa Y, Taniguchi K, Miyazaki C, Momoi MY, Okabe N.

Drug Discov Ther. 2020 Mar 8;14(1):50-53. doi: 10.5582/ddt.2019.01091. Epub 2020 Feb 26.

8.

New insights into the molecular basis of lactase non-persistence/persistence: a brief review.

Kuchay RAH.

Drug Discov Ther. 2020 Mar 8;14(1):1-7. doi: 10.5582/ddt.2019.01079. Epub 2020 Feb 26. Review.

9.

Usefulness of next-generation DNA sequencing for the diagnosis of urinary tract infection.

Ishihara T, Watanabe N, Inoue S, Aoki H, Tsuji T, Yamamoto B, Yanagi H, Oki M, Kryukov K, Nakagawa S, Inokuchi S, Ozawa H, Imanishi T.

Drug Discov Ther. 2020 Mar 8;14(1):42-49. doi: 10.5582/ddt.2020.01000. Epub 2020 Feb 27.

10.

Pulse wave transit time during exercise testing reflects the severity of heart disease in cardiac patients.

Takayanagi Y, Koike A, Kubota H, Wu L, Nishi I, Sato A, Aonuma K, Kawakami Y, Ieda M.

Drug Discov Ther. 2020 Mar 8;14(1):21-26. doi: 10.5582/ddt.2019.01082. Epub 2020 Feb 17.

11.

Functional role of c-Jun NH2-terminal kinase-associated leucine zipper protein (JLP) in lysosome localization and autophagy.

Suzuki R, Gunarta IK, Boldbaatar J, Erdenebaatar P, Odongoo R, Yoshioka K.

Drug Discov Ther. 2020 Mar 8;14(1):35-41. doi: 10.5582/ddt.2020.01001. Epub 2020 Feb 5.

12.

"4+7" city drug volume-based purchasing and using pilot program in China and its impact.

Tang M, He J, Chen M, Cong L, Xu Y, Yang Y, Hou Z, Song P, Jin C.

Drug Discov Ther. 2019;13(6):365-369. doi: 10.5582/ddt.2019.01093.

13.

Feasibility of microbial sample collection on the skin from people in Yaoundé, Cameroon.

Benderli NC, Ogai K, Lloyd YM, Arios JP, Jiyarom B, Awanakam AH, Esemu LF, Hori A, Megnekou R, Leke RGF, Kuraishi T, Okamoto S, Ekali GL.

Drug Discov Ther. 2019;13(6):360-364. doi: 10.5582/ddt.2019.01075.

14.

FADS2 and ELOVL6 mutation frequencies in Japanese Crohn's disease patients.

Motoi Y, Ito Z, Suzuki S, Takami S, Matsuo K, Sato M, Ota Y, Tsuruta M, Kojima M, Noguchi M, Uchiyama K, Kubota T.

Drug Discov Ther. 2019;13(6):354-359. doi: 10.5582/ddt.2019.01081.

15.

Janus microspheres for enhanced enteral drug delivery: Preparation and orientated attachment to a Caco-2 monolayer.

Matsumoto A, Watanabe C, Murakami M.

Drug Discov Ther. 2019;13(6):343-353. doi: 10.5582/ddt.2019.01090.

16.

Methanol extract of Lonicera caerulea var. emphyllocalyx fruit has anti-motility and anti-biofilm activity against enteropathogenic Escherichia coli.

Minami M, Takase H, Nakamura M, Makino T.

Drug Discov Ther. 2019;13(6):335-342. doi: 10.5582/ddt.2019.01087.

17.
18.

Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.

Sugimoto K, Abe I, Minezaki M, Takashi Y, Ochi K, Fujii H, Ohishi H, Yamao Y, Kudo T, Ohe K, Abe M, Ohnishi Y, Shinagawa T, Mukoubara S, Kobayashi K.

Drug Discov Ther. 2019;13(6):322-327. doi: 10.5582/ddt.2019.01085.

19.

Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S-(4-nitrobenzyl)-6-thioinosine.

Uematsu J, Sakai-Sugino K, Kihira-Nakanishi S, Yamamoto H, Hirai K, Kawano M, Nishio M, Tsurudome M, O'Brien M, Komada H.

Drug Discov Ther. 2019;13(6):314-321. doi: 10.5582/ddt.2019.01084.

20.

Gene disruption of ribosomal protein L5 (RPL5) decreased the sensitivity of CHO-K1 cells to uncoupler carbonylcyanide-3-chlorophenylhydrazone.

Araki M, Ishibashi T, Munesue M, Ohashi K, Nobukuni Y, Maeda M.

Drug Discov Ther. 2019;13(6):306-313. doi: 10.5582/ddt.2019.01080.

Supplemental Content

Loading ...
Support Center